

Jaume Alijotas-Reig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6803607/publications.pdf>

Version: 2024-02-01

111
papers

4,485
citations

101496

36
h-index

118793

62
g-index

133
all docs

133
docs citations

133
times ranked

5103
citing authors

#	ARTICLE	IF	CITATIONS
1	Covid-19 and autoimmunity. <i>Autoimmunity Reviews</i> , 2020, 19, 102597.	2.5	418
2	Recurrent miscarriage: causes, evaluation and management. <i>Postgraduate Medical Journal</i> , 2015, 91, 151-162.	0.9	186
3	Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. <i>Autoimmunity Reviews</i> , 2020, 19, 102569.	2.5	173
4	Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 40-53.	2.9	165
5	The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2015, 14, 498-502.	2.5	152
6	Potentiating maternal immune tolerance in pregnancy: A new challenging role for regulatory T cells. <i>Placenta</i> , 2014, 35, 241-248.	0.7	146
7	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. <i>Autoimmunity Reviews</i> , 2015, 14, 387-395.	2.5	121
8	Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?. <i>American Journal of Reproductive Immunology</i> , 2016, 76, 8-28.	1.2	119
9	Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 241-258.	1.6	116
10	Current Concepts and New Trends in the Diagnosis and Management of Recurrent Miscarriage. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 445-466.	0.2	116
11	Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 150-161.	1.3	106
12	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019, 18, 406-414.	2.5	106
13	Late-Onset Inflammatory Adverse Reactions Related to Soft Tissue Filler Injections. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 97-108.	2.9	102
14	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. <i>Thrombosis and Haemostasis</i> , 2014, 112, 727-735.	1.8	102
15	Maternal and foetal angiogenic imbalance in congenital heart defects. <i>European Heart Journal</i> , 2014, 35, 701-707.	1.0	100
16	TNF \pm -senescence initiates a STAT-dependent positive feedback loop, leading to a sustained interferon signature, DNA damage, and cytokine secretion. <i>Aging</i> , 2017, 9, 2411-2435.	1.4	95
17	Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases. <i>Clinical Immunology</i> , 2019, 203, 1-8.	1.4	84
18	Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. <i>Lupus</i> , 2013, 22, 6-17.	0.8	68

#	ARTICLE	IF	CITATIONS
19	Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 730-734.	2.5	63
20	Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome?. <i>Autoimmunity Reviews</i> , 2015, 14, 23-29.	2.5	62
21	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2018, 47, 639-646.	1.8	62
22	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	2.5	62
23	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A preliminary first year report. <i>Lupus</i> , 2012, 21, 766-768.	0.8	61
24	Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 40-55.	0.2	55
25	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , 2020, 59, 1306-1314.	0.9	53
26	Autoimmune/inflammatory syndrome induced by adjuvants "ASIA" related to biomaterials: analysis of 45 cases and comprehensive review of the literature. <i>Immunologic Research</i> , 2018, 66, 120-140.	1.3	52
27	Pregnancy in women with portal vein thrombosis: Results of a multicentric European study on maternal and fetal management and outcome. <i>Journal of Hepatology</i> , 2012, 57, 1214-1219.	1.8	46
28	Endometriosis with infertility: A comprehensive review on the role of immune deregulation and immunomodulation therapy. <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13384.	1.2	45
29	Delayed Immune-Mediated Adverse Effects of Polyalkylimide Dermal Fillers. <i>Archives of Dermatology</i> , 2008, 144, 637-42.	1.7	44
30	Is Obstetric Antiphospholipid Syndrome a Primary Nonthrombotic, Proinflammatory, Complement-Mediated Disorder Related to Antiphospholipid Antibodies?. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 39-45.	0.2	43
31	Inherited antithrombin deficiency and pregnancy: Maternal and fetal outcomes. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 149, 47-51.	0.5	42
32	Fastest molecular photochromic switches based on nanosecond isomerizing benzothiazolium azophenolic salts. <i>Journal of Materials Chemistry C</i> , 2014, 2, 474-480.	2.7	40
33	Delayed Immune-Mediated Adverse Effects Related to Polyacrylamide Dermal Fillers. <i>Dermatologic Surgery</i> , 2009, 35, 360-366.	0.4	38
34	Cell-derived microparticles and vascular pregnancy complications: a systematic and comprehensive review. <i>Fertility and Sterility</i> , 2013, 99, 441-449.	0.5	38
35	Do knowledge of uterine artery resistance in the second trimester and targeted surveillance improve maternal and perinatal outcome? UTOPIA study: a randomized controlled trial. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 680-689.	0.9	38
36	Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2012, 40, 367-369.	0.9	35

#	ARTICLE	IF	CITATIONS
37	Effectiveness and safety of prehospital urapidil for hypertensive emergencies. <i>American Journal of Emergency Medicine</i> , 2001, 19, 130-133.	0.7	34
38	Late-Onset Immune-Mediated Adverse Effects after Poly-<i>i></i>-Lactic Acid Injection in Non-HIV Patients: Clinical Findings and Long-Term Follow-Up. <i>Dermatology</i> , 2009, 219, 303-308.	0.9	33
39	Are Bacterial Growth and/or Chemotaxis Increased by Filler Injections? Implications for the Pathogenesis and Treatment of Filler-Related Granulomas. <i>Dermatology</i> , 2010, 221, 356-364.	0.9	33
40	Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria. <i>Lupus</i> , 2015, 24, 1012-1018.	0.8	33
41	Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 675.	1.0	33
42	Anti-Î2-glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy loss. <i>Fertility and Sterility</i> , 2010, 93, 2330-2336.	0.5	30
43	Autoimmune/inflammatory syndrome (ASIA) induced by biomaterials injection other than silicone medical grade. <i>Lupus</i> , 2012, 21, 1326-1334.	0.8	30
44	Study of biomaterial-induced macrophage activation, cell-mediated immune response and molecular oxidative damage in patients with dermal bioimplants. <i>Immunobiology</i> , 2012, 217, 44-53.	0.8	30
45	Medicalâ€grade silicone induces release of proinflammatory cytokines in peripheral blood mononuclear cells without activating T cells. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2009, 90B, 510-520.	1.6	29
46	Circulating Cell-Derived Microparticles in Women with Pregnancy Loss. <i>American Journal of Reproductive Immunology</i> , 2011, 66, 199-208.	1.2	28
47	Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?. <i>Autoimmunity Reviews</i> , 2018, 17, 739-745.	2.5	26
48	Increased risk of lateâ€onset, immuneâ€mediated, adverse reactions related to dermal fillers in patients bearing <sc>HLAâ€B</sc> *08 and <sc>DRB1</sc> *03 haplotypes. <i>Dermatologic Therapy</i> , 2021, 34, e14644.	0.8	26
49	Smoking during Pregnancy: Changes in Mid-Gestation Angiogenic Factors in Women at Risk of Developing Preeclampsia According to Uterine Artery Doppler Findings. <i>Hypertension in Pregnancy</i> , 2013, 32, 50-59.	0.5	25
50	Immunological and physiopathological approach of COVID-19 in pregnancy. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 39-57.	0.8	25
51	Aspirin Desensitization in the Treatment of Antiphospholipid Syndrome during Pregnancy in ASA-sensitive Patients. <i>American Journal of Reproductive Immunology</i> , 2006, 55, 45-50.	1.2	24
52	Tacrolimus in the Treatment of Chronic and Refractory Late-Onset Immune-Mediated Adverse Effects Related to Silicone Injections. <i>Dermatologic Surgery</i> , 2012, 38, 38-47.	0.4	24
53	Circulating Cellâ€Derived Microparticles in Severe Preeclampsia and in Fetal Growth Restriction. <i>American Journal of Reproductive Immunology</i> , 2012, 67, 140-151.	1.2	24
54	Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 314-318.	1.6	24

#	ARTICLE	IF	CITATIONS
55	Angiogenic Factors and Long-Term Cardiovascular Risk in Women That Developed Preeclampsia During Pregnancy. Hypertension, 2020, 76, 1808-1816.	1.3	23
56	Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study. RMD Open, 2020, 6, e001340.	1.8	23
57	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Medicina Clínica, 2018, 151, 215-222.	0.3	22
58	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. Autoimmunity Reviews, 2020, 19, 102525.	2.5	22
59	Circulating microparticles, lupus anticoagulant and recurrent miscarriages. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 145, 22-26.	0.5	21
60	First trimester serum angiogenic/anti-angiogenic status in twin pregnancies: relationship with assisted reproduction technology. Human Reproduction, 2012, 27, 358-365.	0.4	21
61	Bioengineered hyaluronic acid elicited a nonantigenic T cell activation: Implications from cosmetic medicine and surgery to nanomedicine. Journal of Biomedical Materials Research - Part A, 2010, 95A, 180-190.	2.1	20
62	Síndrome antifosfolípídico obstétrico. Revista Clínica Espanola, 2016, 216, 135-145.	0.2	20
63	Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets. Lupus, 2012, 21, 257-263.	0.8	18
64	Anti-annexin A5 antibodies in women with spontaneous pregnancy loss. Medicina Clínica, 2010, 134, 433-438.	0.3	17
65	Regulatory T cells, maternal "foetal immune tolerance and recurrent miscarriage: New therapeutic challenging opportunities. Medicina Clínica, 2015, 144, 265-268.	0.3	16
66	Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study. Rheumatology, 2022, 61, 1053-1061.	0.9	16
67	ORIGINAL ARTICLE: Are Anti-Beta ₂ -Glycoprotein I Antibodies Markers for Recurrent Pregnancy Loss in Lupus Anticoagulant/Anticardiolipin Seronegative Women?. American Journal of Reproductive Immunology, 2008, 60, 229-237.	1.2	15
68	Recurrent Kikuchi "Fujimoto disease during pregnancy: Report of case evolving into systemic lupus erythematosus and review of published work. Journal of Obstetrics and Gynaecology Research, 2008, 34, 595-598.	0.6	15
69	Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study. American Journal of Perinatology, 2021, 38, 1472-1479.	0.6	15
70	Polymyositis and cyclosporin A.. Annals of the Rheumatic Diseases, 1990, 49, 66-66.	0.5	14
71	Recurrent Urticarial Vasculitis Related to Nonanimal Hyaluronic Acid Skin Filler Injection. Dermatologic Surgery, 2009, 35, 395-398.	0.4	14
72	Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. American Journal of Reproductive Immunology, 2016, 76, 164-171.	1.2	14

#	ARTICLE	IF	CITATIONS
73	Immunological Puzzle Related to Recurrent Miscarriage: Overview. <i>Current Immunology Reviews</i> , 2009, 5, 175-186.	1.2	14
74	Chronic Villitis of unknown etiology (VUE): Obstetrical features, outcome and treatment. <i>Journal of Reproductive Immunology</i> , 2021, 148, 103438.	0.8	14
75	Antinuclear Autoantibodies, Complement Level, Hypergammaglobulinemia and Spontaneous Intrauterine Hematoma in Pregnant Women. <i>American Journal of Reproductive Immunology</i> , 2003, 50, 1-6.	1.2	13
76	Pseudocystic Encapsulation: A Late Noninflammatory Complication of Hyaluronic Acid Filler Injections. <i>Dermatologic Surgery</i> , 2013, 39, 1726-1728.	0.4	13
77	Angiogenic Gene Expression in Down Syndrome Fetal Hearts. <i>Fetal Diagnosis and Therapy</i> , 2016, 40, 21-27.	0.6	12
78	Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial. <i>Fetal Diagnosis and Therapy</i> , 2020, 47, 824-833.	0.6	12
79	Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers: A case series of 20 patients. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 3181-3187.	0.8	11
80	Antiphospholipid antibodies in women with recurrent embryo implantation failure: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 103101.	2.5	9
81	Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria. <i>Rheumatology International</i> , 2020, 40, 777-783.	1.5	8
82	Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes. <i>European Journal of Anaesthesiology</i> , 2021, 38, 916-922.	0.7	8
83	Life-Threatening Bleeding, Pregnancy and Lupus Anticoagulant: Success after Steroid and Anticoagulant Therapy. <i>American Journal of Reproductive Immunology</i> , 2004, 52, 129-132.	1.2	6
84	Acute Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2008, 358, 2744-2746.	13.9	6
85	Cervical pregnancy complicated with group B streptococcal meningitis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2007, 20, 423-425.	0.7	5
86	Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 354-362.	0.8	5
87	Adverse reactions caused by different filler injections in the same region. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 736-737.	1.3	4
88	Embarazo y enfermedades autoinmunitarias. <i>Medicina Clínica</i> , 2017, 148, 161-163.	0.3	4
89	Does incomplete obstetric antiphospholipid syndrome really exist?. <i>Medicina Clínica</i> , 2021, 156, 515-519.	0.3	4
90	Proteomics and enriched biological processes in Antiphospholipid syndrome: A systematic review. <i>Autoimmunity Reviews</i> , 2021, 20, 102982.	2.5	4

#	ARTICLE	IF	CITATIONS
91	Comparing pregnancy outcomes in patients with criteria and non-criteria autoimmune disease: A systematic review. <i>Lupus</i> , 2022, 31, 5-18.	0.8	4
92	Recurrent Kikuchi-Fujimoto necrotizing lymphadenitis during pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 140, 144-145.	0.5	3
93	Foreign-Body Granuloma After Injection of Calcium Hydroxylapatite for Treating Urinary Incontinence. <i>Obstetrics and Gynecology</i> , 2011, 118, 1181-1182.	1.2	3
94	Letter: Vasculitis Related to Non-Animal Hyaluronic Acid Skin Filler Injection. <i>Dermatologic Surgery</i> , 2010, 36, 272-273.	0.4	2
95	Expectant management in pregnant women with early and severe preeclampsia and concomitant risk factors. <i>Pregnancy Hypertension</i> , 2013, 3, 235-241.	0.6	2
96	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 215-222.	0.1	2
97	Letter to the Editor. <i>Lupus</i> , 2004, 13, 554-554.	0.8	1
98	Polyalkylimide Implant: Critical Evaluation of a Clinical Studyâ€”Reply. <i>Archives of Dermatology</i> , 2010, 146, 918.	1.7	1
99	Erratum to Ruffatti et al. â€œTreatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicenter retrospective studyâ€”(Thromb Haemost 2014; 112: 727-725). <i>Thrombosis and Haemostasis</i> , 2014, 112, 1327-1327.	1.8	1
100	Regulatory T cells, maternalâ€œfoetal immune tolerance and recurrent miscarriage: New therapeutic challenging opportunities. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 265-268.	0.1	1
101	Anticuerpos antifosfolÃ­pido, osteonecrosis e infecciÃ³n por el virus de la inmunodeficiencia humana. <i>Medicina Clínica</i> , 2003, 120, 236-236.	0.3	1
102	Sarcoidosis, sÃ­ndrome de LÃ¡ngren y fiebre uveoparotÃ­dea (caso 145-2003). <i>Medicina Clínica</i> , 2004, 123, 478b-478.	0.3	1
103	Inherited Antithrombin Deficiency and Pregnancy: Maternal and Fetal Outcomes. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 366-367.	0.2	0
104	THU0396â€”The Efficacy of Hydroxychloroquine for Obstetrical Outcome in Anti-Phospholipid Syndrome: Data from a European Multicenter Retrospective Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 340.1-340.	0.5	0
105	Pregnancy and autoimmune diseases. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 161-163.	0.1	0
106	Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain. <i>Thrombosis Research</i> , 2017, 156, 195-197.	0.8	0
107	Maternal microbiota and the great obstetrical syndromes: When the enemy becomes an ally. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 141-143.	0.1	0
108	La microbiota materna y los grandes sÃ­ndromes obstÃ©tricos: cuando el enemigo se convierte en aliado. <i>Medicina Clínica</i> , 2018, 150, 141-143.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Does incomplete obstetric antiphospholipid syndrome really exist?. Medicina Clínica (English Edition), 2021, 156, 515-519.	0.1	0
110	Tratamiento de la oftalmopatía de Graves. Medicina Clínica, 2021, 158, 93-93.	0.3	0
111	Treatment of Graves' ophthalmopathy. Medicina Clínica (English Edition), 2022, 158, 93-93.	0.1	0